title: Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: an open label observational study.
authors.forename: N
authors.initials: N
authors.lastname: Assous
authors.forename: L
authors.initials: L
authors.lastname: Gossec
authors.forename: M
authors.initials: M
authors.lastname: Dougados
authors.forename: A
authors.initials: A
authors.lastname: Kahan
authors.forename: Y
authors.initials: Y
authors.lastname: Allanore
mesh_terms: D000328:Adult; D000368:Aged; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000627:therapeutic use*; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy*; D000075202:Contraindications; D004359:Drug Therapy, Combination; D000068800:Etanercept; D005602:France; D006801:Humans; D007074:Immunoglobulin G; D007262:Infusions, Intravenous; D008727:Methotrexate / Q000627:therapeutic use; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor; D000069283:Rituximab; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D018501:Antirheumatic Agents; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000069283:Rituximab; D000068800:Etanercept; D008727:Methotrexate